Permanent neonatal diabetes (PND) is an extremely rare condition. Few cases of PND caused by pancreas-development failure have been described, and only a few genetic causes have been identified so far ([@B1]).

We describe a boy with PND caused by pancreas agenesis, currently age 7 years. He is the first child of healthy, unrelated parents. He was born at 35 weeks of gestation, with severe intrauterine growth restriction (weight 1,620 g; length 45 cm). In the first day of life he developed severe hyperglycemia, and neonatal diabetes was diagnosed and treated with insulin, initially intravenously and then subcutaneously. Atrial septal defect was diagnosed in absence of other dysmorphic features. Pancreas agenesis was detected by ultrasound and then confirmed by magnetic resonance imaging (MRI). Concomitant exocrine pancreas insufficiency was treated with pancreatic enzyme administration. Brain MRI and neurophysiological evaluations (auditory brainstem evoked potential, nerve conduction velocities, and electroencephalogram) were normal. Glycemic control was characterized by severe fluctuations despite a strict dietary regimen and frequent adjustment of insulin dosages.

Stoffers ([@B2]) and Sellick ([@B3]) first described patients with pancreatic agenesis carrying *PDX1* and *Ptf1a* mutations, respectively. Other authors with the intent of revealing or identify the molecular mechanisms that underlie the pancreatic development failure proposed other additional genes as candidates, which they selected based on knowledge derived from human studies ([@B4]).

DNA was extracted from whole blood samples from the patient. Several specific genes, such as *KCNJ11, Sur1, GCK* (involved in PND), *Pdx1* (the key regulator of pancreas development and its promoter sequence upstream \[E-Boxes\]), *Ptf1a, Sox9, Sox17, Hnf6, HlxB9* transcription factors expressed at the early stage, and *HNF4a*, as well as the *NeuroD1, HNF1*α, and *HNF1*β transcription factors expressed at the late stage of the pancreas differentiation, were amplified using specific primer by PCR and analyzed by direct sequencing.

The alignment of the screened gene to the human prototype sequences did not reveal any disease-causing mutations. Only a nonpathological insertion of two GCC triplets was found in the polyalanine stretch encoded in exon 1 of *Hlxb9*. Thus, the patient has 16 instead of 14 alanine, with 11 encoded by the GCC repeat. The study by Ross et al. ([@B5]) did not find any pathogenic association related to the length of polyalanine stretch in the *Hlxb9* gene; we therefore considered this a polymorphism without disease relevance.

We add our case of PND caused by pancreatic agenesis to those already in the literature with normal *Pdx1* and *Ptf1a* genes. Understanding the molecular network involved in the pancreatic development might provide the basis for the elaboration of new cell therapy approaches to treat diabetes ([@B4]).
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